文献速递前列腺癌

恩杂鲁胺联合镭-223在mCRPC中碱性磷酸酶与PSA应答:PEACE-3事后分析

Alkaline Phosphatase and Prostate-specific Antigen Response in Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide Alone or in Combination with Radium-223: Ad Hoc Analysis of the PEACE-3 Consortium Trial.
PubMed 文献 · Eur Urol Oncol · 2026-08-28

PEACE-3试验的探索性事后分析纳入446例无症状或轻度症状的mCRPC骨转移患者,比较恩杂鲁胺单药与联合镭-223对ALP和PSA应答的影响。联合组ALP-30应答率更高且达应答时间更短,PSA-90应答率亦更高,支持镭-223联合恩杂鲁胺具有额外抗肿瘤活性。

要点

  • 联合镭-223使ALP-30确认应答率从50.8%提高至56.5%,应答时间缩短。
  • 联合组PSA-90确认应答率50.5% vs 34.1%,中位应答时间显著缩短。
  • 结果为探索性事后分析,无多重校正,未分析生物标志物应答与临床结局关联。

核心结论

  • 恩杂鲁胺联合镭-223与更快、更频繁的ALP应答和深度PSA应答相关,支持镭-223联合恩杂鲁胺具有额外抗肿瘤活性。

研究设计与样本

  • 国际、随机、开放标签3期PEACE-3试验的探索性事后分析,纳入446例无症状或轻度症状的mCRPC骨转移患者。
  • 441例和436例分别可评估ALP和PSA应答。

主要发现

  • 6个月时确认ALP-30应答率联合组56.5% vs 恩杂鲁胺单药组50.8%。
  • 确认ALP-30应答中位时间2.4 vs 3.7个月(HR 1.41,95%CI 1.12-1.78;p=0.003)。
  • ALP正常化中位时间2.0 vs 4.5个月(HR 2.05,95%CI 1.46-2.88;p<0.001)。
  • 6个月时确认PSA-90应答率50.5% vs 34.1%(p=0.001)。
  • 确认PSA-90应答中位时间5.6 vs 22.1个月(HR 1.48,95%CI 1.13-1.93;p=0.004)。

关键数值与推荐

  • ALP应答定义为较基线下降≥30%(ALP-30),PSA应答定义为下降≥50%(PSA-50)或≥90%(PSA-90)。
  • 确认应答需间隔≥21天的连续测量。
  • 干预为恩杂鲁胺160 mg每日一次,单用或联合镭-223每6个月注射(55 kBq/kg)。

临床怎么用

  • 联合镭-223可能使mCRPC骨转移患者更早出现ALP和PSA深度应答,但需结合临床结局综合判断。

局限性

  • 探索性事后分析设计。
  • 未进行多重性校正。
  • 未分析生物标志物应答与临床结局的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESIGN, SETTING, AND PARTICIPANTS: Exploratory post hoc analysis of the international, randomised, open-label phase 3 PEACE-3 trial including 446 patients with asymptomatic or mildly symptomatic mCRPC and bone metastases. Overall, 441 and 436 patients were evaluable for ALP and PSA, respectively. INTERVENTION: Enzalutamide 160 mg daily alone or combined with six-monthly injections of radium-223 (55 kBq/kg). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: ALP response was defined as a ≥30% decline from baseline (ALP-30), and PSA response as a≥50% decline (PSA-50) or ≥90% decline (PSA-90). Confirmed responses required consecutive measurements ≥21 d apart. Time-to-event endpoints were analysed using Kaplan-Meier and Cox models. RESULTS AND LIMITATIONS: At 6 months, confirmed ALP-30 response was 56.5% with the combination versus 50.8% with enzalutamide alone. Median time to confirmed ALP-30 response was 2.4 versus 3.7 months (hazard ratio [HR] 1.41, 95% confidence interval [CI] 1.12-1.78; p = 0.003), and time to ALP normalisation was 2.0 versus 4.5 months (HR 2.05, 95% CI 1.46-2.88; p < 0.001). Confirmed PSA-90 response at 6 months was 50.5% versus 34.1% (p = 0.001), with median time to confirmed PSA-90 response of 5.6 versus 22.1 months (HR 1.48, 95% CI 1.13-1.93; p = 0.004). Limitations include the exploratory post hoc design, the absence of multiplicity adjustment, and the lack of an analysis linking biomarker responses to clinical outcomes. CONCLUSIONS: Adding radium-223 to enzalutamide was associated with faster and more frequent ALP and deep PSA responses. These findings support additional antitumour activity of radium-223 when combined with enzalutamide.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Soares A, Gillessen S, Choudhury A, et al. Alkaline Phosphatase and Prostate-specific Antigen Response in Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide Alone or in Combination with Radium-223: Ad Hoc Analysis of the PEACE-3 Consortium Trial. Eur Urol Oncol. 2026. PMID: 42665513. doi:10.1016/j.euo.2026.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。